Dow Jones (DJIA) Today: Johnson & Johnson (JNJ) Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Dow Jones Industrial Average ( ^DJI) is trading down 28.0 points (-0.2%) at 17,144 as of Tuesday, Sep 23, 2014, 10:36 a.m. ET. During this time, 68.2 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 298.7 million. The NYSE advances/declines ratio sits at 1,205 issues advancing vs. 1,608 declining with 246 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Holding back the Dow today is Johnson & Johnson (NYSE: JNJ), which is lagging the broader index with an eight-cent decline to $107.80. This single drop is lowering the Dow Jones Industrial Average by 0.61 points or roughly accounting for 2.2% of the Dow's overall loss. Volume for Johnson & Johnson currently sits at 2.7 million shares traded vs. an average daily trading volume of 6.2 million shares.

Johnson & Johnson has a market cap of $304.56 billion and is part of the health care sector and drugs industry. Shares are up 17.8% year-to-date as of Monday's close. The stock's dividend yield sits at 2.6%.

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Trade War Fear Creeps Back Into Markets on Thursday

Trade War Fear Creeps Back Into Markets on Thursday

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Daimler Slumps After Profit Warning Cites 'Import Tariffs' in US-China Trade War

Daimler Slumps After Profit Warning Cites 'Import Tariffs' in US-China Trade War

Oil Prices Slide as Saudi Energy Minister Suggests OPEC Output Deal Imminent

Oil Prices Slide as Saudi Energy Minister Suggests OPEC Output Deal Imminent

5 Biggest U.S. Tech Stocks Test $4 Trillion Valuation Amid Bullish Nasdaq Run

5 Biggest U.S. Tech Stocks Test $4 Trillion Valuation Amid Bullish Nasdaq Run